Key result
Higher circulating MMP8, MMP9, and TIMP1 are linked to increased death and progression in IPF.
Why the study?
The study was conducted to assess the prognostic utility of circulating levels of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in patients with idiopathic pulmonary fibrosis.
Do circulating levels of MMPs and TIMPs predict death and disease progression in patients with idiopathic pulmonary fibrosis?
Cohort (n=300)
Do circulating levels of MMPs and TIMPs predict death and disease progression in patients with idiopathic pulmonary fibrosis?
Circulating levels of MMP8 and TIMP1 may provide prognostic information on the risk of death and disease progression in patients with idiopathic pulmonary fibrosis beyond standard clinical measures.
May inform IPF prognosis beyond clinical factors; leaves open added value for risk stratification or trials.
INTRODUCTION: We assessed the prognostic utility of circulating levels of matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) in patients with idiopathic pulmonary fibrosis (IPF) in the IPF-PRO Registry. METHODS: MMP and TIMP concentrations were quantified by ELISA in plasma from 300 patients. A Cox proportional hazard regression model was used to assess associations between select MMPs and TIMPs and death and disease progression (absolute decline in forced vital capacity ≥10% predicted, death, or lung transplant). RESULTS: Over a median follow-up of 30.4 months, 98 patients died and 182 patients had disease progression. In unadjusted analyses, higher concentrations of MMPs 2, 3, 8 and 9 and TIMPs 1, 2 and 4 were associated with an increased risk of death. MMPs 2 and 8 and TIMP1 remained associated with death after adjustment for clinical factors. In unadjusted analyses, higher concentrations of MMPs 8 and 9 and TIMPs 1 and 4 were associated with an increased risk of disease progression. MMPs 8 and 9 and TIMP1 remained associated with progression after adjustment for clinical factors. CONCLUSION: Circulating levels of MMP8 and TIMP1 may provide information on the risk of outcomes in patients with IPF not captured by clinical measures.
No takes yet. Share an insight, caveat, or question.
Amubieya et al. (2024) conducted a cohort in Idiopathic pulmonary fibrosis (n=300). Circulating matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) was evaluated on Death and disease progression (absolute decline in forced vital capacity ≥10% predicted, death, or lung transplant). Higher circulating levels of MMP8, MMP9, and TIMP1 were associated with increased risk of death (98 of 300 patients) and disease progression (182 of 300 patients) in IPF after clinical adjustment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: